Linear Clinical Research | Perth, Australia

Research site

Site insights

Top conditions

Top treatments


Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 44 total trials

A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors

The goal of this clinical trial is to learn about IOS-1002 in patients with solid tumors.The main questions it aims to answer are:* To determine the...

Solid Tumor, Adult
Drug: IOS-1002 + KEYTRUDA® (pembrolizumab)
Drug: IOS-1002

* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer the...

Active, not recruiting
Advanced or Metastatic Solid Tumors
Drug: Pembrolizumab
Drug: ERAS-601

The primary objective of this study is to evaluate safety and tolerability data when SRSD107 is administered as single and multiple SC injections to...

Drug: Placebo
Drug: SRSD107

This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with sel...

T-cell Lymphoma
Aggressive B-Cell NHL
Drug: PRT2527
Drug: Zanubrutinib

To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors* To evaluate...

Advanced or Metastatic Solid Tumors
Drug: Trametinib
Drug: Naporafenib

The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and...

Vasomotor Symptoms
Adult Healthy Volunteers
Drug: Placebo
Drug: GS1-144

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Solid Tumor, Adult
Drug: KIN-2787 and binimetinib
Drug: KIN-2787

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. T...

Not yet enrolling
Lymphoma, Non-Hodgkin
Drug: DZD8586

This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacoki...

Breast Cancer
Gastric Cancer
Drug: IKS014

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunog...

B-cell Non-Hodgkin Lymphoma
B-cell Lymphoma
Drug: IKS03

The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclo...

Multiple Myeloma
Drug: Elranatamab
Drug: Pomalidomide

This is a double-blind, randomized, placebo-controlled study to assess the safety and PK profile of a single subcutaneous dose of IMG-007 in healthy...

Active, not recruiting
Healthy Volunteers
Drug: IMG-007
Drug: Placebo

The purpose of this study is to assess the safety and tolerability of BGB-A445 alone and in combination with tislelizumab in participants with advanc...

Active, not recruiting
Advanced Solid Tumor
Non Small Cell Lung Cancer
Drug: BGB-A445
Drug: tislelizumab

This is a phase 1b multi-center, open-label study of HMBD-001 in combination with docetaxel with or without cetuximab in participants with locally ad...

Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: HMBD-001

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1...

Locally Advanced Solid Tumor
Metastatic Solid Tumor
Drug: HMBD-001
Drug: Nab-paclitaxel
Locations recently updated

This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislel...

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2
Drug: Tislelizumab
Drug: LBL-007

The primary objectives of this study are : to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administer...

Active, not recruiting
Locally Advanced and Metastatic Solid Tumors
Drug: Nab paclitaxel
Drug: Oxaliplatin

This is a clinical study aiming to assess pharmacokinetics and biomarker evidence of ZE46-0134 efficacy in Healthy Volunteers after single and multip...

Drug: ZE46-0134 or placebo
Drug: Rabeprazole, 20mg oral

This is a dose escalation, Phase 1 study of ABN401 in patients with advanced solid tumors, refractory metastatic disease, or refractory locally advan...

Advanced Solid Tumors
Drug: ABN401- Expansion Phase
Drug: ABN401- Escalation Phase

Trial sponsors

BeiGene logo
Arrowhead Pharmaceuticals logo
Agenus logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems